Novel selective CYP11B1 Inhibitors
Scientists of Saarland University have recently succeeded in developing the first CYP11B1 inhibitors showing good selectivity. As starting point the highly active CYP11B1 inhibitor Etomidate has been used. Via several modifications followed by further optimizations realized at this molecule, it was possible to increase the selectivity resulting in a very weak inhibition towards CYP11B2 and no inhibition of CYP17 and CYP19.
Further Information: PDF
Universität des Saarlandes Wissens- und Technologietransfer GmbH PatentVerwertungsAgentur der saarländischen Hochschulen
Phone: +49 (0)681/302-71302
Contact
Dipl.-Kfm. Axel Koch (MBA), Dr. Conny Clausen, Dr. Hauke Studier, Dr. Susanne Heiligenstein
Media Contact
All latest news from the category: Technology Offerings
Newest articles
Recovering phosphorus from sewage sludge ash
Chemical and heat treatment of sewage sludge can recover phosphorus in a process that could help address the problem of diminishing supplies of phosphorus ores. Valuable supplies of phosphorus could…
Efficient, sustainable and cost-effective hybrid energy storage system for modern power grids
EU project HyFlow: Over three years of research, the consortium of the EU project HyFlow has successfully developed a highly efficient, sustainable, and cost-effective hybrid energy storage system (HESS) that…
After 25 years, researchers uncover genetic cause of rare neurological disease
Some families call it a trial of faith. Others just call it a curse. The progressive neurological disease known as spinocerebellar ataxia 4 (SCA4) is a rare condition, but its…
